The statistical rationale that the DOW is using to justify testosterone screening
Please note this is not a political concern and more a concern about loss medical/shared decision-making.
The prevalence of biochemical hypogonadism ranges from 10-40% in the general population and increases with age
• Baltimore Longitudinal Study of Aging: prevalence of 12% in men 50-59 and over 50% in men over 80 years of age
*(*exceptionally small minority of our patients demographic)
• Armed Forces (2018-2025): the annual prevalence of male hypogonadism ranged from 0.6 to 0.9%
(Fraction of a percentage of patients that MAY qualify)
• Special Operations Forces: small studies estimate male hypogonadism prevalence higher at approximately 39%-43%
(Population that works themselves out to exhaustion and generally sleep deprived)
This policy*** ***will cost taxpayers 58 million annually just for the initial mandatory screening.